{"paper_id": "379dbfef76fdfee936a9ccbaaaaca2a89f11c49c", "metadata": {"title": "Supplementary data to A new oxygen modification cyclooctaoxygen binds to nucleic acids as sodium crown complex", "authors": [{"first": "Andreas", "middle": ["J"], "last": "Kesel", "suffix": "", "affiliation": {}, "email": "andreas.kesel@gmx.de"}, {"first": "Craig", "middle": ["W"], "last": "Day", "suffix": "", "affiliation": {"laboratory": "", "institution": "Utah State University", "location": {"postCode": "84322", "settlement": "Logan", "region": "Utah", "country": "United States"}}, "email": ""}, {"first": "Catherine", "middle": ["M"], "last": "Montero", "suffix": "", "affiliation": {"laboratory": "Laboratory of Biochemical Pharmacology", "institution": "Emory University School of Medicine", "location": {"postCode": "30322", "settlement": "Atlanta", "region": "Georgia", "country": "United States"}}, "email": ""}, {"first": "Raymond", "middle": ["F"], "last": "Schinazi", "suffix": "", "affiliation": {"laboratory": "Laboratory of Biochemical Pharmacology", "institution": "Emory University School of Medicine", "location": {"postCode": "30322", "settlement": "Atlanta", "region": "Georgia", "country": "United States"}}, "email": ""}]}, "abstract": [], "body_text": [{"text": "* The mass error (ppm) was calculated according to [1] . * The time between addition of the 0.694 M Na + -acetate buffer (pH 6.36) and the addition of the last reagent. \u2020 The pH value of the assay solution after addition of the last reagent. \u2021 Detected visually following 10 s moderate shaking of the catalase effect assay 5 ml glass vessel after addition of the last reagent (gas evolution intensity rating: \u2500, no significant gas evolution; +, moderate gas evolution without frothing; ++, moderate to strong gas evolution accompanied by weak frothing; +++, strong gas evolution accompanied by frothing). measure of goodness-of-fit) on EC 50 and EC 90 . AZT, zidovudine (3'-azido-3'-deoxythymidine).", "cite_spans": [{"start": 51, "end": 54, "text": "[1]", "ref_id": "BIBREF3"}], "ref_spans": [], "section": ""}, {"text": "FTC, emtricitabine (2',3'-dideoxy-5-fluoro-3'-thia-\u03b2-L-cytidine). N.D., not determined (because not calculable).", "cite_spans": [], "ref_spans": [], "section": ""}, {"text": "* The given effective inhibitory concentrations (\u00b5M \u00b1 s.d.) for the positive control AZT were averaged and treated statistically from nineteen (n = 19) independent determinations. \u2020 Taken from [2] .", "cite_spans": [{"start": 193, "end": 196, "text": "[2]", "ref_id": "BIBREF4"}], "ref_spans": [], "section": ""}, {"text": "Cytotoxicity CC 50 (\u00b5M) and cellular growth at fixed 100 \u00b5M concentration (%, in parentheses) ", "cite_spans": [], "ref_spans": [], "section": "Drug"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "\u21925')-uridylic acid 2',3'-cyclic phosphate] 2 . [5'-HO-GpU>p \u2261 p<CpA-OH-5'], nonpalindromic double stranded dinucleotide 2", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "SI 50 , selectivity index CC 50 /EC 50 . SI 90 , selectivity index CC 50 /EC 90 . Neutral red, test for lysosomal uptake of 3-amino-7-(dimethylamino)-2-methylphenazine hydrochloride (neutral red vital stain). VYR, virus yield reduction plaque assay of actual virus yield. RIB, ribavirin (1-\u03b2-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide)", "authors": [], "year": null, "venue": "CC 50 , cytotoxic concentration 50%. EC 50 , effective inhibitory concentration 50%. EC 90 , effective inhibitory concentration 90%", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Accurate mass measurement: terminology and treatment of data", "authors": [{"first": "A", "middle": ["G"], "last": "Brenton", "suffix": ""}, {"first": "A", "middle": ["R"], "last": "Godfrey", "suffix": ""}], "year": 2010, "venue": "J. Am. Soc. Mass Spectrom", "volume": "21", "issn": "", "pages": "1821--1835", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication", "authors": [{"first": "S", "middle": ["K"], "last": "Ladner", "suffix": ""}], "year": 1997, "venue": "Antimicrob. Agents Chemother", "volume": "41", "issn": "", "pages": "1715--1720", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronavirus (SARS-CoV) inhibitors", "authors": [{"first": "H.-Z", "middle": [], "last": "Zhang", "suffix": ""}], "year": 2006, "venue": "J. Med. Chem", "volume": "49", "issn": "", "pages": "1198--1201", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "Proton magnetic resonance spectroscopy of cytidine hydrochloride and NC________________________ Fourier transform infrared (FT-IR) spectroscopy of cytidine hydrochloride and NC__________________ Fourier transform Raman (FT-Raman) spectroscopy of cytidine hydrochloride and NC_______________ Electrospray ionization mass spectrometry (ESI-MS) of NC and dNC____________________________ Electrospray ionization mass spectrometry of NC____________________________________________ Fourier transform infrared (FT-IR) spectroscopy of 2'-deoxycytidine hydrochloride and dNC__________ Electrospray ionization mass spectrometry of dNC___________________________________________ Proton magnetic resonance spectroscopy of dNC and RC_____________________________________ 10 Catalase effect assays of NC in absence and presence of C. utilis low-molecular weight RNA or salmon testes ssDNA_________________________________________________________________________________ 11-Fourier transform infrared (FT-IR) attenuated total reflectance (ATR) spectroscopy of cytidine hydrochloride and RC___________________________________________________________________________ 13 Electrospray ionization mass spectrometry of RC___________________________________________ 14 Thin-layer chromatographic mobility shift assay of the binding of NC to C. utilis low-molecular weight RNA_________________________________________________________________________________________ 15-Thin-layer chromatographic mobility shift assay of the binding of NC to salmon testes ssDNA (sonicated salmon testes genomic DNA)_____________________________________________________________________ Thin-layer chromatographic mobility shift assay of the binding of NC to salmon testes ssDNA (sonicated salmon testes genomic DNA) in absence and presence of spermine \u00d7 1 \u2153 (sodium dihydrogen phosphate)", "latex": null, "type": "figure"}, "FIGREF1": {"text": "Proton magnetic resonance spectroscopy of cytidine hydrochloride and NC recorded in deuterated dimethyl sulfoxide. (A) The 700.43 MHz 1 H-NMR spectrum of cytidine \u00d7 HCl dissolved in DMSO-d 6 , together with the atom numbering scheme of cytidine \u00d7 HCl (valid for 2'deoxycytidine \u00d7 HCl, too). (B) The 700.43 MHz 1 H-NMR spectrum of NC dissolved in DMSO-d 6 .", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Fourier transform infrared (FT-IR) spectroscopy of cytidine hydrochloride and NC. (A) The FT-IR spectrum of cytidine \u00d7 HCl recorded in KBr pellet. (B) The FT-IR spectrum of NC recorded in KBr pellet.", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Fourier transform Raman (FT-Raman) spectroscopy of cytidine hydrochloride and NC. (A) The FT-Raman spectrum of cytidine \u00d7 HCl recorded with neat crystalline solid. (B) The FT-Raman spectrum of NC recorded with neat crystalline solid.", "latex": null, "type": "figure"}, "FIGREF4": {"text": "Electrospray ionization mass spectrometry (ESI-MS) of NC and dNC. (A) The ESI-MS spectrum of NC dissolved in aqueous methanol (1.2 mg/ml). (B) The magnified (5 \u00d7) ESI-MS spectrum of dNC dissolved in methanol (1.9 mg/ml).", "latex": null, "type": "figure"}, "FIGREF5": {"text": "Electrospray ionization mass spectrometry of NC.", "latex": null, "type": "figure"}, "FIGREF6": {"text": "Fourier transform infrared (FT-IR) spectroscopy of 2'-deoxycytidine hydrochloride and dNC. (A) The FT-IR spectrum of 2'-deoxycytidine \u00d7 HCl recorded in KBr pellet. (B) The FT-IR spectrum of dNC recorded in KBr pellet.", "latex": null, "type": "figure"}, "FIGREF7": {"text": "Electrospray ionization mass spectrometry of dNC.Fig. S8. Proton magnetic resonance spectroscopy of dNC and RC recorded in deuterated dimethyl sulfoxide. (A) The 700.43 MHz 1 H-NMR spectrum of dNC dissolved in DMSO-d 6 . (B) The 700.43 MHz 1 H-NMR spectrum of RC dissolved in DMSO-d 6 .", "latex": null, "type": "figure"}, "FIGREF8": {"text": "Catalase effect assays of NC in absence and presence of C. utilis low-molecular weight RNA or salmon testes ssDNA.", "latex": null, "type": "figure"}, "FIGREF9": {"text": "Fourier transform infrared (FT-IR) attenuated total reflectance (ATR) spectroscopy of cytidine hydrochloride and RC. (A) The FT-IR spectrum of cytidine \u00d7 HCl recorded neat by ATR. (B) The FT-IR spectrum of RC recorded neat by ATR.", "latex": null, "type": "figure"}, "FIGREF10": {"text": "Electrospray ionization mass spectrometry of RC.", "latex": null, "type": "figure"}, "FIGREF11": {"text": "Thin-layer chromatographic mobility shift assay of the binding of NC to C. utilis lowmolecular weight RNA. (1) Cytidine \u00d7 HCl, incubation at RT for 3 h 15 min, 40 \u00b5l solution on spot. (2) NC, incubation at RT for 3 h 15 min, 40 \u00b5l solution on spot. (3) C. utilis RNA, incubation of the C. utilis low-molecular weight RNA stock suspension at RT for 3 h 15 min, 80 \u00b5l colloidal solution on spot. (4) C. utilis RNA + NC, 1,000 \u00b5l C. utilis low-molecular weight RNA colloidal stock solution added to 500 \u00b5l of NC stock solution, incubation at RT for 3 h, 80 \u00b5l colloidal solution on spot. (5) C. utilis RNA + cytidine \u00d7 HCl, 1,000 \u00b5l C. utilis low-molecular weight RNA colloidal stock solution added to 500 \u00b5l of cytidine \u00d7 HCl stock solution, incubation at RT for 3 h, 80 \u00b5l colloidal solution on spot. RNase A, paired (including two palindromic sequences) and unpaired RNA dinucleotides representing human skin RNase A (RNase 7)-produced enzymatic degradation products of C. utilis tRNA and C. utilis 5S rRNA. 5'-HO-ApC>p, adenosinyl(3'\u21925')cytidylic acid 2',3'-cyclic phosphate. 5'-HO-GpC>p, guanosinyl(3'\u21925')-cytidylic acid 2',3'-cyclic phosphate. 5'-HO-ApU>p, adenosinyl(3'\u21925')-uridylic acid 2',3'-cyclic phosphate. 5'-HO-GpU>p, guanosinyl(3'\u21925')-uridylic acid 2',3'-cyclic phosphate. [5'-HO-GpC>p] 2 , palindromic [guanosinyl(3'\u21925')-cytidylic acid 2',3'-cyclic phosphate] 2 . [5'-HO-ApU>p] 2 , palindromic", "latex": null, "type": "figure"}, "FIGREF12": {"text": "Thin-layer chromatographic mobility shift assay of the binding of NC to salmon testes ssDNA (sonicated salmon testes genomic DNA). (1) Cytidine \u00d7 HCl, incubation at RT for 1 h 15 min, 40 \u00b5l solution on spot. (2) NC, incubation at RT for 1 h 15 min, 40 \u00b5l solution on spot. (3) Salmon testes ssDNA, 100 \u00b5l salmon testes ssDNA colloidal stock solution diluted with 300 \u00b5l H 2 O, incubation at RT for 55 min, 80 \u00b5l colloidal solution on spot. (4) Salmon testes ssDNA + NC, 700 \u00b5l salmon testes ssDNA colloidal stock solution added to 500 \u00b5l of NC stock solution, incubation at RT for 1 h, 80 \u00b5l colloidal solution on spot. (5) Salmon testes ssDNA + cytidine \u00d7 HCl, 200 \u00b5l salmon testes ssDNA colloidal stock solution added to 500 \u00b5l of cytidine \u00d7 HCl stock solution, incubation at RT for 1 h, 80 \u00b5l colloidal solution on spot.", "latex": null, "type": "figure"}, "FIGREF13": {"text": "Thin-layer chromatographic mobility shift assay of the binding of NC to salmon testes ssDNA (sonicated salmon testes genomic DNA) in absence and presence of spermine \u00d7 1 \u2153 (sodium dihydrogen phosphate) \u00d7 9 H 2 O. (1) Cytidine \u00d7 HCl, incubation at RT for 1 h, 40 \u00b5l solution on spot. (2) NC, incubation at RT for 1 h, 40 \u00b5l solution on spot. (3) Salmon testes ssDNA, incubation at RT for 40 min, 40 \u00b5l colloidal salmon testes ssDNA stock solution neat on spot. (4) Salmon testes ssDNA + NC + spermine \u00d7 1 \u2153 (sodium dihydrogen phosphate) \u00d7 9 H 2 O, 200 \u00b5l freshly shaken suspension (in H 2 O) of spermine \u00d7 1 \u2153 (sodium dihydrogen phosphate) \u00d7 9 H 2 O added to 500 \u00b5l of salmon testes ssDNA + NC colloidal solution (= 5, incubated at RT for 10 min), shaking of the resulting suspension, incubation at RT for 35 min, 80 \u00b5l supernatant on spot. (5) Salmon testes ssDNA + NC, 700 \u00b5l salmon testes ssDNA colloidal stock solution added to 500 \u00b5l of NC stock solution, incubation at RT for 45 min, 80 \u00b5l colloidal solution on spot. (6) Salmon testes ssDNA + cytidine \u00d7 HCl, 200 \u00b5l salmon testes ssDNA colloidal stock solution added to 500 \u00b5l of cytidine \u00d7 HCl stock solution, incubation at RT for 45 min, 80 \u00b5l colloidal solution on spot. (7) Salmon testes ssDNA + cytidine \u00d7 HCl + spermine \u00d7 1 \u2153 (sodium dihydrogen phosphate) \u00d7 9 H 2 O, 200 \u00b5l freshly shaken suspension (, incubation at RT for 35 min, 80 \u00b5l supernatant on spot.", "latex": null, "type": "figure"}, "TABREF0": {"text": "", "latex": null, "type": "table"}, "TABREF1": {"text": "Cytotoxicity and antiviral activity of NC and dNC versus human immunodeficiency type 1 and hepatitis B viruses in mammalian cells_______________________________________________________________________ 20 Cytotoxicity and antiviral activity of NC versus influenza A, chikungunya and Middle East respiratory syndrome viruses in mammalian cells______________________________________________________________ 21-22", "latex": null, "type": "table"}, "TABREF2": {"text": "Cytotoxicity and antiviral activity of NC and dNC versus human immunodeficiency type 1 and hepatitis B viruses in mammalian cells. CC 50 , cytotoxic concentration 50%. EC 50 , effective inhibitory concentration 50%. EC 90 , effective inhibitory concentration 90%. SI 50 , selectivity index CC 50 /EC 50 . r 2 , coefficient of determination (r 2", "latex": null, "type": "table"}, "TABREF3": {"text": "Anti-HIV-1 LAI activity EC 50 (\u00b5M)/EC 90 (\u00b5M) and rate of HIV-1 LAI replication in PBM cells at fixed 100 \u00b5M concentration (%, in parentheses) HBV ayw activity EC 50 (\u00b5M)/EC 90 (\u00b5M) and rate of HBV ayw production from HepAD38 cells at fixed 100 \u00b5M concentration (%, in parentheses)", "latex": null, "type": "table"}, "TABREF4": {"text": "Cytotoxicity and antiviral activity of NC versus influenza A, chikungunya and Middle", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Drug </td><td>Cytotoxicity CC50 (\u00b5M) </td><td>(H1N1) activity EC50 </td><td>Anti-influenza A/California/07/2009 virus (\u00b5M)/EC90 </td><td>(\u00b5M) in </td></tr><tr><td>MDCK </td><td>Assay type </td><td>EC50 </td><td>EC90 </td><td>MDCK cells SI50 </td><td>SI90 </td></tr><tr><td>NC </td><td>&gt; 1,000 </td><td>Neutral red </td><td>&gt; 1,000 </td><td>N.D. </td><td>N.D. </td><td>N.D. </td></tr><tr><td>NC </td><td>&gt; 1,000 </td><td>VYR </td><td>N.D. </td><td>&gt; 1,000 </td><td>N.D. </td><td>N.D. </td></tr><tr><td>RIB </td><td>&gt; 1,310 </td><td>Neutral red </td><td>53.2 \u00b1 </td><td>N.D. </td><td>&gt; 24.6 </td><td>N.D. </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>18.4 </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>RIB </td><td>&gt; 1,310 </td><td>VYR </td><td>N.D. </td><td>21.3 \u00b1 7.8 </td><td>N.D. </td><td>&gt; 61.5 </td></tr></table></body></html>"}}, "back_matter": [{"text": "East respiratory syndrome viruses in mammalian cells. ", "cite_spans": [], "ref_spans": [], "section": "annex"}]}